DNA methylation in personalized medicine

Personalized Medicine

Volumn 8, Issue 1, 2011, Pages 35-43

  Budiman, Muhammad A ^a   Smith, Steven W ^b   Ordway, Jared M ^a  

^a Orion Genomics   (United States)

^b Genesmith Informatics LLC   (United States)

Author keywords

companion diagnostics; epigenetics; loss of imprinting; next generation sequencing; technology

Indexed keywords

BISULFITE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

BREAST CANCER; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE AMPLIFICATION; GENETIC ASSOCIATION; HUMAN; NUCLEOTIDE SEQUENCE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TECHNOLOGY;

EID: 78650624128     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.10.72     Document Type: Review

References (71)

1. Strahl BD, Allis CD: The language of covalent histone modifcations. Nature 403(6765), 41-45 (2000).
2. Shiio Y, Eisenman RN: Histone sumoylation is associated with transcriptional repression. Proc Natl Acad. Sci. USA 100(23), 13225-13230 (2003).
3. Guil S, Esteller M: DNA methylomes, histone codes and miRNAs: tying it all together. Int. J. Biochem. Cell Biol. 41(1), 87-95 (2009).
4. Lan J, Hua S, He X, Zhang Y: DNA methyltransferases and methyl-binding proteins of mammals. Acta. Biochim. Biophys. Sin. (Shanghai) 42(4), 243-252 (2010).
5. Lister R, Pelizzola M, Dowen RH et al.: Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271), 315-322 (2009).
6. Saxonov S, Berg P, Brutlag DL: A genome-wide ana lysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters. Proc. Natl Acad. Sci. USA 103(5), 1412-1417 (2006).
7. Shen L, Kondo Y, Guo Y et al.: Genome-wide profling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 3 (10), 2023-2036 (2007).
8. Illingworth R, Kerr A, Desousa D et al.: A novel CpG island set identifes tissue-specifc methylation at developmental gene loci. PLoS Biol. 6(1), e22 (2008).
9. Onyango P, Miller W, Lehoczky J et al.: Sequence and comparative ana lysis of the mouse 1-megabase region orthologous to the human 11p15 imprinted domain. Genome Res. 10(11), 1697-1710 (2000).
10. Ball MP, Li JB, Gao Y et al.: Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat. Biotechnol. 27(4), 361-368 (2009).
11. Song F, Mahmood S, Ghosh S et al.: Tissue specifc differentially methylated regions (TDMR): changes in DNA methylation during development. Genomics 93(2), 130-139 (2009).
12. Ordway JM, Budiman MA, Korshunova Y et al.: Identifcation of novel high-frequency DNA methylation changes in breast cancer. PLoS ONE 2(12), e1314 (2007).
13. Yoder JA, Walsh CP, Bestor TH: Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 13(8), 335-340 (1997).
14. Smit AF: Interspersed repeats and other mementos of transposable elements in mammalian genomes. Curr. Opin. Genet. Dev. 9(6), 657-663 (1999).
15. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 31 (1), 27-36 (2010).
16. Davalos V, Esteller M: MicroRNAs and cancer epigenetics: a macrorevolution. Curr. Opin. Oncol. 22(1), 35-45 (2010).
17. President's Council of Advisors on Science and Technology (US): Priorities for Personalized Medicine Washington, DC, USA (2008).
18. Sauter G, Lee J, Bartlett JM et al.: Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J. Clin. Oncol. 27(8), 1323-1333 (2009).
19. Hughes T, Deininger M, Hochhaus A et al.: Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108(1), 28-37 (2006).
20. Allegra CJ, Jessup JM, Somerfeld MR et al.: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J. Clin. Oncol. 27(12), 2091-2096 (2009).
21. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89-92 (1983).
22. Gama-Sosa MA, Slagel VA, Trewyn RW et al.: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11(19), 6883-6894 (1983).
23. Goelz SE, Vogelstein B, Hamilton SR et al.: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228(4696), 187-190 (1985).
24. Feinberg AP, Gehrke CW, Kuo KC et al.: Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 48(5), 1159-1161 (1988).
25. Ehrlich M: DNA hypomethylation in cancer cells. Epigenomics 1(2), 239-259 (2009).
26. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7(1), 21-33 (2006).
27. Hu M, Yao J, Cai L et al.: Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 37(8), 899-905 (2005).
28. Hochedlinger K, Blelloch R, Brennan C et al.: Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 18(15), 1875-1885 (2004).
29. Weller M, Stupp R, Reifenberger G et al.: MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 6(1), 39-51 (2010).
30. Pegg AE: Repair of O(6)-alkylguanine by alkyltransferases. Mutat. Res. 462(2-3), 83-100 (2000).
31. Hegi ME, Diserens AC, Gorlia T et al.: MGMT gene silencing and beneft from temozolomide in glioblastoma. N Engl. J. Med. 352(10), 997-1003 (2005).
32. Tilghman SM, Bartolomei MS, Webber AL et al.: Parental imprinting of the H19 and Igf2 genes in the mouse. Cold Spring Harb. Symp. Quant. Biol. 58, 287-295 (1993).
33. Rainier S, Johnson LA, Dobry CJ et al.: Relaxation of imprinted genes in human cancer. Nature 362(6422), 747-749 (1993).
34. Ogawa O, Eccles MR, Szeto J et al.: Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362(6422), 749-751 (1993).
35. Kaneda A, Feinberg AP: Loss of imprinting of IGF2: a common epigenetic modifer of intestinal tumor risk. Cancer Res. 65(24), 11236-11240 (2005).
36. Cui H, Horon IL, Ohlsson R et al.: Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med. 4(11), 1276-1280 (1998).
37. Cui H, Cruz-Correa M, Giardiello FM et al.: Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299(5613), 1753-1755 (2003).
38. Sakatani T, Wei M, Katoh M et al.: Epigenetic heterogeneity at imprinted loci in normal populations. Biochem. Biophys. Res. Commun. 283(5), 1124-1130 (2001).
39. Cruz-Correa M, Zhao R, Oviedo M et al.: Temporal stability and age-related prevalence of loss of imprinting of the insulin-like growth factor-2 gene. Epigenetics 4(2), 114-118 (2009).
40. Woodson K, Flood A, Green L et al.: Loss of insulin-like growth factor-II imprinting and the presence of screen-detected colorectal adenomas in women. J. Natl Cancer Inst. 96(5), 407-410 (2004).
41. Kaneda A, Wang CJ, Cheong R et al.: Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc. Natl Acad. Sci. USA 104(52), 20926-20931 (2007).
42. Timp W, Levchenko A, Feinberg AP: A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction. Cell Cycle 8(3), 383-390 (2009).
43. Simon R: Clinical trials for predictive medicine: new challenges and paradigms. Clin. Trials 7(5), 516-524 (2010).
44. Laird PW: Principles and challenges of genome-wide DNA methylation ana lysis. Nat. Rev. Genet. 11(3), 191-203 (2010).
45. Huang YW, Huang TH, Wang LS: Profling DNA methylomes from microarray to genome-scale sequencing. Technol. Cancer Res. Treat. 9(2), 139-147 (2010).
46. Yan PS, Potter D, Deatherage DE et al.: Differential methylation hybridization: profling DNA methylation with a high-density CpG island microarray. Methods Mol. Biol. 507, 89-106 (2009).
47. Khulan B, Thompson RF, Ye K et al.: Comparative isoschizomer profling of cytosine methylation: the HELP assay Genome Res. 16(8), 1046-1055 (2006).
48. Oda M, Glass JL, Thompson RF et al.: High-resolution genome-wide cytosine methylation profling with simultaneous copy number ana lysis and optimization for limited cell numbers. Nucleic Acids Res. 37(12), 3829-3839 (2009).
49. Stewart FJ, Panne D, Bickle TA et al.: Methyl-specifc DNA binding by McrBC, a modifcation-dependent restriction enzyme. J. Mol. Biol. 298(4), 611-622 (2000).
50. Lippman Z, Gendrel AV, Black M et al.: Role of transposable elements in heterochromatin and epigenetic control. Nature 430(6998), 471-476 (2004).
51. Lippman Z, Gendrel AV, Colot V et al.: Profling DNA methylation patterns using genomic tiling microarrays. Nat. Methods 2(3), 219-224 (2005).
52. Ordway JM, Bedell JA, Citek RW et al.: Comprehensive DNA methylation profling in a human cancer genome identifes novel epigenetic targets. Carcinogenesis 27(12), 2409-2423 (2006).
53. Irizarry RA, Ladd-Acosta C, Carvalho B et al.: Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res. 18(5), 780-790 (2008).
54. Ibrahim AE, Thorne NP, Baird K et al.: MMASS: an optimized array-based method for assessing CpG island methylation. Nucleic Acids Res. 34(20), e136 (2006).
55. Rollins RA, Haghighi F, Edwards JR et al.: Large-scale structure of genomic methylation patterns. Genome Res. 16(2), 157-163 (2006).
56. Weber M, Hellmann I, Stadler MB et al.: Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat. Genet. 39(4), 457-466 (2007).
57. Weber M, Davies JJ, Wittig D et al.: Chromosome-wide and promoter-specifc analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37(8), 853-862 (2005).
58. Keshet I, Schlesinger Y, Farkash S et al.: Evidence for an instructive mechanism of de novo methylation in cancer cells. Nat Genet. 38(2), 149-153 (2006).
59. Zhang X, Yazaki J, Sundaresan A et al.: Genome-wide high-resolution mapping and functional ana lysis of DNA methylation in arabidopsis. Cell 126(6), 1189-1201 (2006).
60. Gebhard C, Schwarzfscher L, Pham TH et al.: Rapid and sensitive detection of CpG-methylation using methyl-binding (MB)-PCR. Nucleic Acids Res. 34(11), e82 (2006).
61. Gebhard C, Schwarzfscher L, Pham TH et al.: Genome-wide profling of CpG methylation identifes novel targets of aberrant hypermethylation in myeloid leukemia. Cancer Res. 66(12), 61 18-6128 (2006).
62. Schmidl C, Klug M, Boeld TJ et al.: Lineage-specifc DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res. 19(7), 1165-1174 (2009).
63. Jorgensen HF, Adie K, Chaubert P et al.: Engineering a high-affnity methyl-CpG-binding protein. Nucleic Acids Res. 34(13), e96 (2006).
64. Rauch T, Pfeifer GP: Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab. Invest. 85(9), 1172-1180 (2005).
65. Rauch TA, Pfeifer GP: The MIRA method for DNA methylation ana lysis. Methods Mol. Biol. 507, 65-75 (2009).
66. Rauch TA, Zhong X, Wu X et al.: High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc. Natl Acad. Sci. USA 105(1), 252-257 (2008).
67. Hill VK, Hesson LB, Dansranjavin T et al.: Identifcation of 5 novel genes methylated in breast and other epithelial cancers. Mol. Cancer 9, 51 (2010).
68. Down TA, Rakyan VK, Turner DJ et al.: A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome ana lysis. Nat. Biotechnol. 26(7), 779-785 (2008).
69. Frommer M, McDonald LE, Millar DS et al.: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89(5), 1827-1831 (1992).
70. Eid J, Fehr A, Gray J et al.: Real-time DNA sequencing from single polymerase molecules. Science 323(5910), 133-138 (2009).
71. Flusberg BA, Webster DR, Lee JH et al.: Direct detection of DNA methylation during single-molecule, real-time sequencing. Nat. Methods 7(6), 461-465 (2010).